DESTINY-Lung04 III期临床研究显示,优赫得®一线治疗HER2突变晚期非小细胞肺癌患者的中位无进展生存期达14.3个月

美通社
Yesterday

中位无进展生存期相较于帕博利珠单抗联合化疗延长了6个月 阿斯利康和第一三共的优赫得®是首个在该治疗领域的III期临床研究中,证实优于标准治疗方案、可延缓疾病进展的HER2靶向疗法 上海2026年9月14日 /美通社/ -- DESTINY-Lung04 III期临床研究结果显示:阿斯利康和第一三共共同开发和商业化的优赫得®(英文商品名:Enhertu®,通用名:注射用德曲妥珠单抗)一线治疗不可切除...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10